Becton, Dickinson and Company (NYSE:BDX) EVP Sells $13,961.20 in Stock

Key Points

• Executive stock sale: Becton Dickinson EVP Michael Feld sold 76 shares for $13,961.20 under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings by 0.39% to 19,644 shares.
• Solid quarterly results: BD reported quarterly EPS of $3.23, beating estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company guided to fiscal 2026 EPS of $12.62–$12.72.
• Stock and analyst view: Shares recently traded at $182.03, near their 52-week high, with analysts split between Buy and Hold ratings and an average price target of $187.67. BD also declared a $1.05 quarterly dividend, representing a 2.3% yield.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 76 shares of the company's stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $183.70, for a total value of $13,961.20. Following the sale, the executive vice president owned 19,644 shares of the company's stock, valued at approximately $3,608,602.80. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $188.49, for a total value of $31,100.85.
• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $157.13, for a total value of $11,784.75.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $1.80 during trading hours on Tuesday, hitting $182.03. 1,528,588 shares of the stock were exchanged, compared to its average volume of 1,722,243. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company's 50 day moving average is $179.26 and its 200 day moving average is $161.33. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market capitalization of $50.16 billion, a P/E ratio of 54.83, a P/E/G ratio of 12.96 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the prior year, the company earned $3.68 earnings per share. The business's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BDX. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Citigroup reiterated a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Piper Sandler boosted their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Finally, Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $187.67.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently modified their holdings of the stock. SHP Wealth Management acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at $26,000. Meeder Asset Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $29,000. Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $29,000. Finally, Kelleher Financial Advisors bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth about $30,000. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.